Introduction
============

Posttransplant lymphoproliferative disorder (PTLD) is a well-known, potentially fatal complication of solid organ transplantation (SOT) with high mortality (30%--60%)[@B1]. The incidence of PTLD in SOT recipients varies from 1% to 13% depending on the type of allograft, ages of recipients and the length of follow-up[@B2][@B3]. The majority of PTLD cases are associated with Epstein-Barr virus (EBV) infection, either primary infection or reactivation due to immunosuppression[@B4]. Risk factors of PTLD include EBV-naïve recipients with EBV-positive donors, younger age at SOT, more aggressive immunosuppression, and within the first year of SOT[@B5].

In pediatric allograft transplantation, PTLD is relatively common because the recipients are often EBV seronegative at the time of transplantation[@B5]. As Korean experience, Heo et al.[@B6] had reported 5 cases of PTLD among 41 pediatric liver allograft recipients (12.2%) in 2004. Another study of 43 Korean PTLD cases reported 12 pediatric cases, but the incidence among pediatric SOT recipients was not described[@B7]. Recently, our center has experienced several consecutive cases of pediatric PTLD, which lead us to review the clinical spectrum of PTLD in pediatric SOT recipients. In this study, we present our experience of pediatric PTLD of 20 years.

Materials and methods
=====================

We retrospectively reviewed the medical records of PTLD cases among pediatric SOT recipients of liver (LT) or kidney transplantation (KT) that had been performed from January 1995 to December 2014 at Seoul National University Children\'s Hospital. The study was approved by the Institutional Review Boards of our center (IRB\#H-1312-068-541). PTLD was clinically suspected when SOT recipients presented persistent lymphadenopathy or tumorous lesions, which were confirmed pathologically and classiied following the classification of the World Health Organization system[@B8]. We categorized the patients into the malignant group and the benign group according to the pathology. Early PTLD was defined as PTLD occurring within the first year of SOT[@B5]. EBV association was assessed in tissue specimens by *in situ* hybridization of Epstein-Barr virus encoded RNA. EBV viral loads in the patients were measured by real-time polymerase chain reaction of EBV DNA in the peripheral blood of the patients.

Characteristics of the patients were reviewed as follows: clinical features at the time of transplantation (underlying disease, transplanted organ, age at transplantation, EBV serologic status of the donor and the recipient at transplantation, Human Leukocyte Antigen \[HLA\] typing); posttransplantation history (rejection episode, immunosuppressive treatment, cytomegalovirus \[CMV\] reactivation status); and characteristics of PTLD (clinical presentation, histopathologic diagnosis, expression of CD20 on tumor cells, detection of EBV in tumor cells, stage, treatment, outcome, graft survival, overall survival \[OS\]). OS is defined as the duration from diagnosis of PTLD to the last follow-up or death. Clinical staging was performed retrospectively according to the Ann Arbor staging system for lymphoma[@B9].

Differences between PTLD patient subsets were assessed by chi-square test for categorized variables and Welch-Aspin test for continuous variables. A *P* value of less than 0.05 was considered statistically significant. The statistical analysis was performed using IBM SPSS Statistics ver. 23.0 (IBM Co., Armonk, NY, USA).

Results
=======

1. Characteristics of PTLD patients ([Table 1](#T1){ref-type="table"})
----------------------------------------------------------------------

Over the last 2 decades (January 1995 to December 2014), 18 patients (LT:KT, 11:7) were diagnosed with PTLD, rendering the incidence of PTLD 4.8% for pediatric LT (of total 230 recipients) and 2.9% for pediatric KT (of 234 cases). For these PTLD cases, median age at transplantation was 11 months (range, 3 months to 18 years) and PTLD was diagnosed at median 7 months (range, 2 to 98 months) after SOT, mostly during the first year (n=14, 77.7%), at their median age of 51 months (range, 10 months to 18 years). KT patients with PTLD were older at SOT (median age, 76 months; range 44 months to 13 years) than LT recipients (median age, 7 months; range, 3 to 18 months) on their diagnosis of PTLD.

All patients with PTLD were taking tacrolimus targeting trough levels of 10--15 mg/mL in immediate postoperation periods, then 6--8 mg/mL (before 2012) or 8--10 mg/mL (since 2012) for KT and 5--8 ng/mL for LT. Basiliximab was administered in eight patients as induction immunosuppression, and 6 of LT patients with PTLD were treated for acute rejection before diagnosis of PTLD. EBV serology of the recipients at the time of SOT was antibody negative in 7, positive in 5, and unknown in 6. HLA types of the patients were predominantly HLA-A2, A33, B44, B58, DR13, and DR15. None of the patients had malignancy before SOT.

Since we recently experienced several consecutive cases of PTLD we compared recent cases with those before 2012 ([Table 2](#T2){ref-type="table"}). While KT cases were more common after 2012 along with different age at SOT and PTLD ([Fig. 1A](#F1){ref-type="fig"}), there were no statistically significant differences in time interval between SOT to PTLD, immunosuppression, EBV viral load, or pathologic malignancy ([Fig. 1B](#F1){ref-type="fig"}).

2. Presentation of PTLD ([Table 3](#T3){ref-type="table"})
----------------------------------------------------------

Initial symptoms of PTLD were mostly fever (n=10, 55.6%) or gastrointestinal problems, such as abdominal pain, vomiting, diarrhea, and blood tinged stool (n=11, 61.1%). Fifteen patients had lymph node enlargement (83.3%) and 3 patients had mass or nodular lesions (16.7%), mostly in the intraperitoneal cavity. The majority of the patients had gastrointestinal organ involvement, including small bowel (n=9, 50%) and intraperitoneal lymph nodes (n=8, 44.4%).

Pathologic diagnosis of PTLD revealed 5 cases of early lesion (27.8%), 4 cases of polymorphic type (22.2%), 1 case of monomorphic type (5.6%), 4 cases of diffuse large B-cell lymphoma (22.2%), 3 cases of Burkitt lymphoma (16.7%), and 1 case of malignant lymphoblastic lymphoma (5.6%). CD20 expression of tumor was positive in all patients tested (n=17), suggesting B-cell proliferation. Seventeen patients showed EBV positive-tumors (94.4%). At the time of PTLD diagnosis, EBV viral loads were 555--3,506,000 copies/mL whole blood (median, 166,571 copies/mL) when measured (n=15). Four patients showed evidence of CMV coinfection by CMV IgM seroprevalence, CMV antigenemia or CMV viral load, reactivation in two and *de novo* infection in others.

When compared to benign PTLD patients (median, 6.5 months after SOT), those with malignant PTLD seemed to be diagnosed with PTLD later (median, 9 months after SOT), although there was no statistically significant difference ([Table 4](#T4){ref-type="table"}), and female patients seemed to be common in the malignant group (*P*=0.058). There was no statistically significant difference in B symptoms, involved organs, or EBV titers at diagnosis of PTLD.

3. Treatment and outcome
------------------------

Upon recognition of PTLD, maintenance immunosuppression was reduced in all patients, similar to what was reported in the literature[@B10][@B11], and additional treatments were applied as appropriate ([Table 3](#T3){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}). Surgery was considered as the primary treatment for localized lesion and primary tumors were removed by surgery in one third of the patients (n=6, 33.3%). Rituximab (RTX) was administered in every case since 2013 and one malignant case in 2006 (72.2%). Before RTX was established as the first line treatment for PTLD, ganciclovir (GCV) had been tried as an initial treatment of PTLD (n=6). GCV was also used along with RTX when there was CMV coinfection (patient numbers 7 and 16). Chemotherapy was administered for malignant PTLD (n=8). The first line chemotherapy in our institute was CCG 106B protocol[@B12] (prednisolone, vincristine, daunomycin, cyclophosphamide, and intrathecal chemotherapy of cytarabine, hydrocortisone, and methotrexate) along with RTX.

All patients achieved complete remission of PTLD ([Fig. 2](#F2){ref-type="fig"}). Four patients achieved remission with GCV monotherapy, and 2 patients (patient numbers 12 and 18) achieved remission with RTX monotherapy. Median OS was 35 months (range, 3 months to 12 years). However, patient number 11 lost her allograft kidney during chemotherapy, and patient number 6 expired from complication of chemotherapy (sepsis) with functioning graft after achieving remission of malignant lymphoma. At last follow-up, all the surviving patients showed no evidence of PTLD, and their EBV titers were median 3,145 copies/mL (range, 0--43,101 copies/mL).

DISCUSSION
==========

In the early 2000s, our center experienced its first PTLD cases. Similar to the observations of others[@B5] this coincided with the introduction of tacrolimus, which replaced cyclosporine as the main immunosuppressant at our institute in June 2001. After starting regular monitoring of EBV viral load in 2007 and adjusting immunosuppressant accordingly, PTLD cases at our center decreased. However in 2013, recent consecutive cases of PTLD emerged once again. The majority of recent cases were KT recipients and the rate of malignant lymphoma seemed high, while statistically not significant. Changes in the clinical practice for KT recipients before the recent emergence of PTLD patients were not evident, except that the target trough level of tacrolimus was increased from 6--8 to 8--10 ng/mL since 2012. Otherwise characteristics of PTLD patients were similar between those before 2012 and after 2012, except their age at SOT; Generally LT patients are younger than KT patients at SOT, since their common cause of organ failure is biliary atresia in Korea[@B13], and PTLD incidence is higher in LT patients along the line that younger age at SOT is a known risk factor of PTLD. While our number of patients was too small to do statistically appropriate analysis, it seems that with higher target trough level of tacrolimus, the main immunosuppressive agent for SOT, rendered KT patients after 2012 prone to PTLD, as much as younger age of recipient does.

Nevertheless, the clinical spectrum of our cases of PTLD were similar to what is known; the median age at the time of PTLD (4 years) and interval between PTLD diagnosis and transplantation (7 months) of our pediatric PTLD cohort are similar to those reported by Opelz and Döhler[@B5]. We achieved complete remission in every case with a low rate of graft loss (5.6%), which is much higher than reported in the early 2000\'s[@B14][@B15] but similar to those of a recent report[@B16]. In order to assess risk factors of PTLD among pediatric SOT recipients, comparison between patients with PTLD and without PTLD should be done, which is beyond the scope of this report and it is the limitation of this report; Among the known risk factors[@B14], frequency of CMV infection in our cases was 22%, not different from known frequency of CMV in pediatric SOT recipients of one forth[@B17]. HLA types of recipients A2, A11, A26, B5, B8, B18, B21, B38 and B40 had been reported to be of risk of PTLD[@B18][@B19][@B20][@B21], and in our cases HLA-A2 was common; however in Korean population HLA A2 is common[@B15], therefore significance thereof is yet elusive.

What called our attention during our review of pediatric PTLD cases again was that patients who were diagnosed at their early disease status suffered much less than those who found to have PTLD at later stage. While all the patients achieved remission eventually, those malignant cases had to experience long periods of chemotherapy and concomitant complications, including neutropenic fever, graft loss, and death due to sepsis. On the other hand, RTX with reduction of immunosuppression was enough to induce complete remission if the lesion was localized and benign, as experienced by patient numbers 12 and 18. These 2 patients were under surveillance because there was a sudden increase of EBV viral load, therefore more careful physical examination could detect well-defined benign lesion rather early, and they achieved remission without any severe complication. Therefore, we emphasize that early diagnosis and early intervention with appropriate management is necessary for good outcome of PTLD as reported in many studies[@B16][@B22][@B23].

For early detection and furthermore prevention of PTLD, monitoring EBV viral load is considered as one of the crucial factors, even though the specificity and positive predictive value of EBV titer in predicting PTLD are still controversial[@B24][@B25][@B26][@B27]. As an example, right after that regular EBV viral load monitoring was adopted as standard clinical practice, our center encountered only one case of pediatric PTLD during 2008--2012; Upon recognition of high titer of EBV of \>10,000 copies/mL immunosuppression was reduced when possible, and active surveillance of PTLD was adopted. While active monitoring of EBV viral load might not enough to overcome the hazardous effect of more aggressive immunosuppression as suspected as predisposing factor for our recent PTLD cases, we need to monitor EBV infection meticulously, since this is the only tool available to prevent PTLD.

In conclusion, during 20 years of SOT, our center experienced 18 cases of pediatric PTLD (3.9% of pediatric SOT). Most of the patients presented with abdominal symptom, and 44% were malignant. Higher incidence of PTLD coincided with the introduction of Tac and probably also with a higher target trough level of Tac. The outcomes of our PTLD patients were favorable with remission achievement in all patients and a low rate of graft loss and mortality. While previously considered as a fatal complication of SOT, the outcome of PTLD has much improved these days, and active monitoring of EBV infection might reduce this complication of pediatric SOT even further.
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![The annual occurrence of posttransplantation lymphoproliferative disorder in Seoul National University Children\'s Hospital presented according to transplanted organ (A) and pathologic malignancy (B). LT, liver transplantation; KT, kidney transplantation.](kjped-60-86-g001){#F1}

![Treatment and response. RI, reduction of immunosuppression; Chemo, chemotherapy; RTX, rituximab; GCV, ganciclovir; NR, no response; CR, complete remission; R-ICE, rituximab, ifosfamide, carboplatin, etoposide. ^\*^CCG 106B protocol. (GCV) GCV was used for CMV coinfection. ^†^Expired from complication of chemotherapy (sepsis) after remission of posttransplantation lymphoproliferative disorder (PTLD). ^‡^Graft loss during chemotherapy after remission of PTLD.](kjped-60-86-g002){#F2}

###### Characteristics of patients (n=18)

![](kjped-60-86-i001)

  Characteristic                           Value
  ---------------------------------------- ---------------------
  Sex                                      
   Male:female                             9:9
  Organ transplanted                       
   Liver:kidney                            11:7
  Age at transplantation                   11 mo (3 mo--18 yr)
  Donor type                               
   Deceased                                3 (16.7)
   Living related                          15 (83.3)
  Prophylactic basiliximab^\*^             8 (44.4)
  Rejection history and treatment          6 (33.3)
   Steroid                                 3
   Increasing Immunosuppressant            2
   Re-TPL                                  1
  Age at PTLD                              4 yr (10 mo--18 yr)
  Time since transplantation               7 mo (2 mo--98 mo)
   Early:late                              14:4
  EBV serologic status (recipient/donor)   
   EBV VCA IgG(-/+)                        3 (16.7)
   EBV VCA IgG(-/NA)                       4 (22.2)
   EBV VCA IgG(+/+)                        4 (22.2)
   EBV VCA IgG(+/NA)                       1 (5.6)
   EBV VCA IgG(NA/+)                       4 (22.2)
   EBV VCA IgG(NA/NA)                      2 (11.1)

Values are presented as number, median (range), or number (%).

TPL, transplantation; PTLD, posttransplantation lymphoproliferative disorder;

EBV, Epstein-Barr virus; VCA, viral capsid antigen; NA, not available.

^\*^All done for acute rejection prophylaxis right after transplantation.

###### Characteritics of PTLD patients before and after 2012

![](kjped-60-86-i002)

  Variable                        Before 2012 (n=9)            After 2012 (n=9)           *P* value
  ------------------------------- ---------------------------- -------------------------- -----------------------
  Sex                                                                                     
   Male:female                    5:4                          4:5                        0.637^\*^
  Transplanted organ                                                                      
   Liver:kidney                   8:1                          3:6                        0.016^\*^
  Age at transplantation          7 mo (3 mo--53 mo)           71 mo (8 mo--18 yr)        0.032^†^
  Age of PTLD                     1 yr (10 mo--5 yr)           6 yr (1 yr--18 yr)         0.027^†^
  Time since transplantation      7M (3 mo--5 yr)              8 mo (2 mo--8 yr)          0.724^†^
  Tacrolimus dosage (mg/kg/day)   0.154 (0.037--0.526)         0.222 (0.034--0.889)       0.552^†^
  Basiliximab prophylaxis         1 (11.1)                     7 (77.8)                   0.004^\*^
  History of acute rejection      3 (33.3)                     3 (33.3)                   1.000^\*^
  Ann Arbor stage ≥III            5 (55.6)                     6 (66.7)                   0.629^\*^
  B symptoms^‡^                   4 (44.4)                     6 (66.7)                   0.343^\*^
  GI involvement                  7 (77.8)                     4 (44.4)                   0.147^\*^
  Extranodal involvement          7 (77.8)                     5 (55.6)                   0.317^\*^
  Early lesion:malignancy         4:3 (44.4:33.3)              1:5 (11.1:55.6)            0.114^\*^ : 0.343^\*^
  EBV viral load (copies/mL)      261,159 (1,830--3,506,000)   166,571 (555--2,583,544)   0.763^†^

Values are presented as number, median (range), or number (%).

PTLD, posttransplantation lymphoproliferative disorder; GI, gastrointestinal; EBV, Epstein-Barr virus.

^\*^*P* value by chi-square test. ^†^*P* value by Welch-Aspin test. ^‡^B symptoms: night sweats, weight loss of \>10% or fevers.

###### Clinical features at the time of presentation of PTLD, 1st line treatment, and outcome

![](kjped-60-86-i003)

  Case No./sex/age/year of Dx.   Underlying disease/type of SOT/time from SOT to PTLD   Immunosuppression (mg/kg/day)               Presentation                                              Involved site                                                                                                                                                           Ann Arbor stage   Histologic Dx.                                    EBV viral load (copies/mL whole blood)   Treatment other than immunesuppression reduction   OS (mo)
  ------------------------------ ------------------------------------------------------ ------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ------------------------------------------------- ---------------------------------------- -------------------------------------------------- ---------
  1/F /1 yr /2003                Biliary atresia/LT/7 mo                                Tac (0.294)                                 Abdominal mass, intussusception                           Small bowel, mesenteric LNs                                                                                                                                             2B                Early lesion^†,‡^                                 NA                                       Surgery, GCV                                       149
  2/M/10 mo/2005                 Biliary atresia//LT/3 mo                               Tac (0.889), Pd (0.666)                     Fever, diarrhea                                           Paraaortic, aortocaval, mesenteric, inguinal LNs, small bowel                                                                                                           3B                Early lesion^†,‡^                                 NA (+CMV)                                GCV                                                125
  3/M /1 yr/2006                 Biliary atresia/LT/3 mo                                Tac (0.316), Pd (0.316)                     Fever, blood tinged stool                                 Large bowel, splenomegaly                                                                                                                                               2B                Monomorphic type^†,‡^                             775,600                                  GCV                                                120
  4/M/5 yr/2006                  Biliary atresia/LT/60 mo                               Tac (0.087)                                 Fever, melena, abdominal pain                             Small bowel                                                                                                                                                             4B                Burkitt lymphoma^†,‡^                             48,000                                   Surgery, GCV, Chemotherapy, RTX                    117
  5/M/2 yr/2006                  Alagille syndrome/LT/6 mo                              Tac (0.05)                                  Diarrhea, blood tinged stool                              Colon                                                                                                                                                                   2A                Polymorphic type^†,‡^                             413,800 (+CMV)                           GCV                                                117
  6/F/4 yr/2006                  Biliary atresia/LT/42 mo                               Tac (0.034)                                 Fever, abdominal pain, abdominal mass, eriorbital edema   Paratracheal LNs, periorbital soft tissue, paranasal sinuses, pericardium, intraperitoneal mass, stomach, small bowel, peritoneum, omentum, mesentery, kidney nodules   4B                Malignant lymphoma, lymphoblastic, B-lineage^†^   NA                                       Surgery, GCV, Chemotherapy, RTX                    3^\*^
  7/M/10 mo/2007                 Byler disease/LT/10 mo                                 Tac (0.222), Pd (0.555)                     Vomiting, blood tinged stool                              Submandibular, cervical, paraaortic, mesenteric LNs, small bowel, colon, splenomegaly                                                                                   3A                Early lesion^†,‡^                                 3,506,000 (+CMV)                         RTX (GCV)                                          106
  8/F/5 yr/2007                  FSGS/KT/9 mo                                           Tac (0.187), MMF (26.74), Pd (0.134)        Fever, cough, cervical LNE                                Neck mass, jugular LNs, portocaval LN                                                                                                                                   3B                Diffuse large B-cell lymphoma^†,‡^                1,830                                    Chemotherapy, RTX                                  101
  9/F/11 mo/2009                 Biliary atresia/LT/4 mo                                Tac (0.4), Pd (0.2)                         Fever                                                     Mesenteric LNs                                                                                                                                                          2B                Early lesion^‡^ (CD20 staining not done)          108,517                                  GCV                                                73
  10/F/6 yr/2013                 FSGS/KT/5 mo                                           Tac (0.076), Pd (0.19), Sirolimus (0.075)   Vomiting, abdominal pain                                  Cervical, axillary, inguinal LNs, stomach, small bowel, umbilicus, vagina                                                                                               4A                Diffuse large B-cell lymphoma^†,‡^                166,571                                  Surgery, Chemotherapy, RTX                         34
  11/F/13 yr/2013                FSGS/KT/4 mo                                           Tac (0.154), MMF (9.23), Pd (0.064)         Epigastric pain                                           Cervical LNs, tonsil, diaphragmatic LNs, subpleural nodules, lung, stomach, duodenum, mesenteric nodules                                                                4A                Diffuse large B-cell lymphoma^†,‡^                152,987                                  Chemotherapy, RTX                                  34^§^
  12/M/1 yr/2013                 Osteogenesis imperfecta/LT/9 mo                        Tac (0.236)                                 Fever, rash                                               Cervical, paratracheal, carinal, paraesophageal, mesenteric LNs                                                                                                         3B                Polymorphic type^†,‡^                             2,583,544                                RTX                                                33
  13/F/1 yr/2013                 Biliary atresia/LT/3 mo                                Tac (0.432), Pd (0.74)                      Fever                                                     Cervical, mediastinal, mesenteric, retroperitoneal, inguinal LNs, liver, spleen, scalp                                                                                  4B                Diffuse large B-cell lymphoma^†,‡^                1,726,477                                Chemotherapy, RTX                                  32
  14/M/4 yr/2013                 Biliary atresia/LT/43 mo                               Tac (0.037)                                 Fever, abdominal pain                                     Supraclavicular, paratracheal, hilar LNs, lung, liver, subhepatic mass, bowel, peritonium, spleen                                                                       4B                Burkitt lymphoma^†,‡^                             184,217                                  Chemotherapy, RTX                                  27^∥^
  15/F/15 yr/2013                Congenial renal hypoplasia/KT/98 mo                    Tac (0.069), AZT (0.69)                     Diarrhea, abdominal mass with tenderness                  Perigastric, mesenteric LNs, stomach, small bowel                                                                                                                       4A                Burkitt lymphoma^†,‡^                             27,161                                   Chemotherapy, RTX                                  26
  16/M/18 yr/2014                FSGS/KT/2 mo                                           Tac (0.526), MMF (12.63), Pd (0.088)        Head and neck LNE                                         Cervical LNs                                                                                                                                                            1A                Polymorphic type^†,‡^                             555 (+CMV)                               Surgery, RTX (GCV)                                 17
  17/F/7 yr/2015                 Congenital nephrotic syndrome/KT/8 mo                  Tac (0.25), Pd (0.125)                      Tonsilar hypertrophy                                      Bilateral tonsils, cervical LNs                                                                                                                                         1A                Early lesion^†,‡^                                 32,286                                   Surgery, RTX                                       7
  18/M/4 yr/2015                 MCDK/KT/9 mo                                           Tac (0.128), Pd (0.16)                      Fever, cervical LNE                                       Cervical LNs                                                                                                                                                            1B                Polymorphic type^†,‡^                             637,031                                  RTX                                                4

LT, liver transplantation; KT, kidney transplantation; OS, overall survival; FSGS, focal segmental glomerulosclerosis; MCDK, multicystic dysplastic kidney; NA, not available; LN, lymph node; LNE, lymph node enlargement; Ag, CMV antigenemia; PCR, viral load polymerase chain reaction; Tac, tacrolimus; Pd, prednisolone; MMF, mycophenolate mofetil; AZT, azathioprine; RTX, rituximab; GCV, ganciclovir.

^\*^Expired from complication of chemotherapy (sepsis) after remission of PTLD. ^†^CD20 positive. ^‡^EBV In situ hybridization positive. (GCV) GCV was used for CMV coinfection. (+CMV) CMV infection at PTLD diagnosis. ^§^Graft loss during chemotherapy after remission of PTLD. ^∥^On maintenance chemotherapy on last follow-up.

###### Comparison of malignancy group with benign group
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  Variable                        Malignancy (n=8)             Benign (n=10)             *P* value
  ------------------------------- ---------------------------- ------------------------- -----------
  Sex                                                                                    
   Male:female                    2:6                          7:3                       0.058^\*^
  Transplanted organ                                                                     
   Liver:kidney                   4:4                          7:3                       0.387^\*^
  Age at transplantation          53 mo (5 mo --13 yr)         10 mo (3 mo --18 yr)      0.724^†^
  Date of transplantation, year   2005 (2001--2013)            2008 (2003--2014)         0.588^†^
  Age of PTLD                     5 yr (1 yr --15 yr)          1Y (10 mo --18 yr)        0.207^†^
  Date of PTLD                    2013 (2006--2013)            2008 (2003--2015)         0.534^†^
  Time since transplantation      9 mo (3 mo --8 yr)           6.5 mo (2 mo --9 mo)      0.059^†^
  Tacrolimus dosage (mg/kg/day)   0.082 (0.037--0.432)         0.272 (0.050--0.889)      0.042^†^
  Basiliximab prophylaxis         4 (50)                       4 (40)                    0.671^\*^
  History of acute rejection      2 (25)                       3 (30)                    0.737^\*^
  B symptoms^‡^                   5 (62.5)                     5 (50)                    0.596^\*^
  GI involvement                  6 (75)                       5 (50)                    0.280^\*^
  Extranodal involvement          7 (87.5)                     5 (50)                    0.094^\*^
  EBV viral load (copies/mL)      100,494 (1,830--1,726,477)   70,402 (555--3,506,000)   0.221^†^

Values are presented as number, median (range), or number (%).

PTLD, posttransplantation lymphoproliferative disorder; GI, gastrointestinal; EBV, Epstein-Barr virus.

^\*^P value by chi-square test. ^†^*P* value by Welch-Aspin test. ^‡^B symptoms: night sweats, weight loss of \>10% or fevers.
